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ATP1A3 mutations have been described all over the world. Classically, 
rapid-onset dystonia-parkinsonism (RDP); cerebellar ataxia, pes cavus, optic 
atrophy, and sensorineural hearing loss (CAOS/CAPOS) syndrome; and 
alternating hemiplegia of  childhood (AHC) type 2 have been related to this 
gene mutation, although mixed phenotypes have been increasingly reported. 
Paroxysmal dyskinesias include a wide spectrum of  diseases that are charac-
terized by movement disorders, epilepsy, and neurological deficits.1,2 Herein, 
we report a pair of  monozygotic twins carrying an ATP1A3 variant who 
developed paroxysmal dystonic spells resembling non-kinesigenic dyskinesia 
(PNKD) and more severe episodes similar to status dystonicus.
Twenty-year-old monozygotic twins (case 1 and 2) presented during the 
first months of  life with paroxysms of  hyperkinetic movements character-
ized by painful abnormal postures lasting from minutes to hours, 
presenting up to 20 times per week. These movements were triggered by 
weather changes, mood swings, caffeine intake, exercise, fever, and infec-
tions, among others. Later on, they were also characterized by speech 
arrest. Both parents and two more siblings (21 and 11 years old) did not 
show any neurological disease. The 67-year-old paternal grandfather 
developed a dystonic head tremor at 65 years of  age.
Neurologic examination of  case 1 showed interictal generalized dystonic 
postures mainly affecting the axial muscles and both upper extremities (par-
ticularly distally and more severe on the right) as well as both legs, also caus-
ing scissoring gait. Case 2 presented a similar distribution but with an overall 
milder phenotype. Dystonic spells involved the whole body in both cases, in 
some cases reaching the severity of  status dystonicus. Speech arrest was a 
feature that was also observed during these spells (Video 1).
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Abstract
Background:  Paroxysmal movement disorders are a heterogeneous group of  neurological diseases, better understood in recent years thanks to widely available 
genetic testing.
Case report:  A pair of  monozygotic twins with dystonia and paroxysmal attacks, resembling paroxysmal non-kinesigenic dyskinesias, due to a novel ATP1A3 
variant are reported. The complete resolution of  their paroxysms was achieved using levodopa and deep brain stimulation of  the internal globus pallidus. 
Improvement of  interictal dystonia was also achieved with this therapy.
Discussion:  Paroxysmal worsening of  movement disorders should be suspected as part of  the ATP1A3 spectrum. Treatment outcome might be predicted based 
on the phenotype.
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Blood and cerebrospinal fluid (CSF) testing as well as electroen-
cephalography and brain magnetic resonance imaging (MRI) were 
unremarkable. Neuropsychological assessment revealed borderline 
intelligence in both cases (case 1: IQ 72; case 2, IQ 75) with an advan-
tage in verbal comprehension scale, deficiencies in focal, selective, and 
sustained attention; limitation of  working memory which compro-
mises execution of  mathematical and reading comprehension, with 
deficits in codification memory process in verbal tasks and recall mem-
ory process in visual tasks. Processing speed, visuospatial, construc-
tional, and executive functions (abstract thinking) were also impaired; 
case 1 also showed self-monitoring and inhibitory control deficiencies 
with motor perseveration (Table 1).
Genetic testing for PKND mutations was negative. SCL2A1  
(solute carrier family 2 member 1, also known as GLUT-1) mutations 
were not sought since both CSF glucose and lactate levels were 
normal, and patients did not show improvement on following 
a ketogenic diet. Whole exome sequencing showed a novel heterozy-
gous missense variant of  the ATP1A3 gene [Chr19(GRCh37): 
g.42474553A>C NM_001256214.1: c.2444T>G p.(Leu815Arg)] 
classified as probably pathogenic based on the recommendations of  
the American College of  Medical Genetics (ACMG), and Human 
Gene Mutation Database (HGMD) number CM145544. Also, in sil-
ico analysis (SIFT (sorting intolerant from tolerant)) establishes it as 
deleterious and the mutation tester establishes it as pathogenic. 
CADD score of  28.4 and REVEL score of  0.972 were obtained. 
However, we were unable to calculate MetaLR. This finding was 
also replicated in the affected sibling. Genetic testing for this specific 
ATP1A3 variant was negative among their parents, siblings, and 
paternal grandfather.
Levodopa/carbidopa titrated up to 1 gram daily was tried in both twins, 
with complete resolution of  paroxysms and marked improvement of  inter-
ictal dystonia in case 2. Case 1 instead required bilateral internal globus 
pallidus deep brain stimulation (GPi DBS), which resulted in a remission of  
paroxysms and improvement of  interictal dystonia (total UDRS pre-GPi 
DBS: 50/120, 4 months post-GPi DBS: 28/120) (Video 2).
Discussion
Currently, the known genes underlying the pathogenesis of  parox-
ysmal dyskinesias are PRRT2 (phenotype MIM 128200, locus MIM 
614386), PNKD (phenotype MIM 118800, locus MIM 609023), 
SLC2A1/GLUT-1 (phenotype MIM 601042, locus MIM 138140), 
SCN8A (phenotype MIM 602066, locus MIM 600702), KCNMA1 (phe-
notype MIM 609446, locus MIM 600150), ECHS1 (phenotype MIM 
616277, locus MIM 602292), PDHA1 (phenotype MIM 312170, locus 
MIM 300502), PDHX (phenotype MIM 245349, locus MIM 608769), 
DLAT (phenotype MIM 245348, locus MIM 608770), ADCY5 (pheno-
type MIM 606703, locus MIM 600293), CACNA1A (phenotype MIM 
108500 and 141500, locus MIM 601011), GCH1 (phenotype MIM 
128230, locus MIM 600225), and SLC16A2 (phenotype MIM 300523, 
locus MIM 300095).1,2,3 In our cases, the ATP1A3 variant produces a 
phenotype similar to PNKD, particularly the wide range of  duration 
and frequency, the lack of  sudden movement or exercise as precipi-
tant, and the presence of  aggravating factors such as stress and 
fatigue.1,2 However, in contrast to PNKD, our patients also presented 
with interictal mild dystonia, speech arrest, and intellectual disability. 
Nevertheless, interictal neurological deficits and a wide clinical over-
lap have been described among subjects with paroxysmal dyskine-
sias.1,2 Although a de novo mutation is suspected in our cases, the 
paternal grandfather who started with late-onset dystonic tremor, 
tested negative for ATP1A3. The reason for this remains unknown but 
germinal mosaicism has been recently reported as a mechanism of  
inheritance in ATP1A3.4 Nevertheless, there is still a possibility that the 
reported variant lacks pathogenicity among these subjects, mainly 
Case 1 Case 2
Video 1. The Video Shows the Dystonic Posturing Seen in Case 1, while Minor Dystonia Was Noted in Case 2 during Interictal State. The 
second segment of  the video shows paroxysmal dystonic attacks in both cases. 
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explained by its absence in their grandfather and responsiveness to the 
aforementioned treatment.
The large variety of  phenotypes due to mutations in the ATP1A3 
coupled with clinical features shared with other diseases presents a diag-
nostic challenge. ATP1A3-related disorders, such as AHC, RDP, and 
CAPOS syndrome, are just some of  the overlapping entities that share 
common features: abrupt-onset, asymmetric anatomical distribution, 
and association with triggering factors. However, recent descriptions of  
diseases with different mutations at the ATP1A3 have shown some simi-
larities to those already known: fever-induced paroxysmal weakness and 
encephalopathy,5 epilepsy with early death and failure to thrive,6 and 
relapsing encephalopathy with cerebellar ataxia,7 among others. Other 
defects associated with less-specific phenotypes are seizures, dystonia, 
ataxia, and psychiatric conditions.8
Pathophysiological mechanisms involved in the development of  
ATP1A3-related disorders are largely unknown. ATP1A3 encodes the α3 
Table 1.  Results of  Neuropsychological Assessment
CASE 1 CASE 2
Percentile Rank Qualitative Description Percentile Rank Qualitative Description
Intelligence (WAIS-IV)
Full-scale (intellectual quotient) 3 Borderline 5 Borderline
Verbal comprehension 14 Below average 16 Below average
Perceptual reasoning 2 Deficient 4 Borderline
Working memory 1 Deficient 1 Deficient
Processing speed 1 Deficient 6 Borderline
Attention
Stroop interference index 5 Borderline 1 Deficient
Language
Test Barcelona fluency and grammar - Average - Average
Semantic verbal fluency 5 Borderline 15 Below average
Test Barcelona verbal repetition - Average - Average
Test Barcelona complex verbal 
comprehension
10 Below average 10 Below average
Test Barcelona Text reading - Slow with additions and substitutions - Slow with additions
Memory
CVLT word list learning - Below average - Deficient
CVLT word list recall - Average - Average
Test Batrcelona texts memory 10 Below average 40 Average
Test Barcelona visual memory 1 Deficient 1 Deficient
Rey–Osterrieth complex figure recall 1 Deficient 2 Deficient
Visuospatial skills
Rey–Osterrieth complex figure copy 1 Deficient 10 Below average
Test Barcelona constructional praxis 1 Deficient 10 Below average
Executive functions
ToL total moves 74 Average 74 Average
ToL rule violations 1 Deficient 21 Below Average
ToL initiation time 82 Above average 72 Average
ToL execution time 5 Borderline 13 Below Average
Abbreviations: CVLT, California Verbal Learning Test; ToL: Tower of  London Drexel University; WAIS-IV: Wechsler Adult 
Intelligence Scale.
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catalytic subunit of  the Na+/K+ ATPase pump, and it is selectively 
expressed in neurons in the central nervous system. In those expressing 
α3 mutant alleles, reduced affinity of  the Na+/K+ ATPase for intracel-
lular Na+ leads to elevated intracellular Na+ concentrations, which in 
turn can result in an increased influx of  Ca2+ ions in the cell, via the 
Na+/Ca2+ exchange system, with toxic effects and possible liberation of  
excitatory amino acids. Moreover, since the neuronal uptake of  some 
neurotransmitters relies on a correct Na+ gradient, its reduction, due to 
increased intracellular Na+, could functionally impair dopamine uptake, 
thus leading to dystonia and parkinsonism without degeneration of  the 
nigrostriatal pathway.9
A clinical condition similar to PNKD has been described as part of  
the spectrum of  ATP1A3 mutations.10 Pittock et al.11 described an Irish 
family with RDP and one of  the members (case II-9) showed “intermit-
tent episodes of  difficulty speaking, spasms of  his arm and hand and 
unsteadiness in association with stress and anxiety.” This case was cata-
logued by the authors as an atypical presentation of  RDP. Three more 
subjects depicted mild dystonia in this family but were classified as part 
of  the features of  RDP.11 Neither levodopa nor pallidotomy resulted in 
improvement of  the symptoms featured in this family. Rosewich et al.12 
subsequently described 24 subjects with AHC, 23 of  whom had 
dystonia as part of  their clinical presentation, in most cases with onset 
during the first year of  life. Choreoathetosis, dysarthria, hypotonia, 
intellectual disability, and ataxia were also observed in these subjects. 
Roubergue et al.13 described six family members and three had paroxys-
mal exercise-induced dystonia. Lastly, in a review by Sweeney et al.14 in 
2015, “dystonic spells” are described as part of  the clinical criteria for 
AHC but no mention of  paroxysmal dyskinesias is made.
Treatment remains symptomatic. Interestingly, case 2 responded to 
levodopa while case 1 had an excellent response to GPi DBS. Neither 
levodopa nor GPi DBS have been previously reported to successfully 
treat subjects with ATP1A3 mutations.15,16 Nevertheless, resolution of  
paroxysmal episodes in our case is in line with the reports of  significant 
and sustained improvement in subjects with PNKD after undergoing 
bilateral GPi DBS.17 The reason for improvement through levodopa 
being limited to one of  the two cases remains unclear; however, 
levodopa has been shown to improve different entities where dystonia 
coexists: Parkinson’s disease dystonic features, myoclonus dystonia, and 
dopa-responsive dystonia, among others.18–20 A milder phenotype in 
one of  the cases could be the reason for responsiveness to levodopa. It 
seems that a reduced activity at the nigrostriatal dopaminergic system 
would be responsible for the emergence of  dystonia as the causative 
mechanism.
In conclusion, this is the first description of  an ATP1A3 variant caus-
ing paroxysmal worsening of  dystonia resembling PNKD and status 
dystonicus in more severe episodes.21 Our cases suggest that ATP1A3 
mutations should be considered in early onset generalized dystonia 
especially when combined with intellectual disability and paroxysmal 
movement disorders.
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